Cite
HARVARD Citation
Sugahara, K. et al. (n.d.). Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. British journal of pharmacology. pp. 15-27. [Online].